DECIMS Logo mit Schrift

Open menu

Einzelnachweise

    1. ↑ Jacobs LD et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343:898-904.
    2. ↑ 2,0 2,1 Comi G et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study (ETOMS). Lancet 2001; 357:1576-82.
    3. ↑ Kappos L et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006; 67:944-53.
    4. ↑ Kinkel RP et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. (CHAMPIONS) Neurology 2006; 66:678-84.
    5. ↑ 5,0 5,1 Kappos L et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007; 370:389-97.
    6. ↑ 6,0 6,1 6,2 Comi G et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374(9700):1503-11.
    7. ↑ Comi G et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler 2013; 19(8):1074-83.
    8. ↑ Brex PA et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346:158-64.
    9. ↑ 9,0 Clerico et al. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.Cochrane Database Syst Rev. 2008 Apr 16;(2):CD005278
    10. ↑ 10,0 Kappos L et al. BEtaferon in Newly Emerging multiple sclerosis For Initial Treatment (BENEFIT). Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242–9.
    11. ↑ 11,0 Filippini G et al. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. Cochrane Database Syst Rev. 2017 Apr 25;4:CD012200. doi: 10.1002/14651858.CD012200.pub2.